Tychon Biosciences is a biotechnology company commercializing novel technology in the rapidly expanding Immuno-oncology marketplace that offers similar high-specificity cancer killing relative to recently-approved cancer therapies, yet with increased safety and decreased cost. Using Tychon’s BiND platform, a first-in-class bi-specific nanoring platform as an immediate therapy that targets both an antigen receptor on a cancer cell, and T-cell—binding them together and allowing your T-cells to attack cancer cells naturally without the need for genetic engineering.
Company Details
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.tychonbio.com/
Tychon Biosciences Questions
Tychon Biosciences's website is https://www.tychonbio.com/
Tychon Biosciences's LinkedIn profile is https://www.linkedin.com/company/tychon-biosciences
Tychon Biosciences's industry is
Biotechnology Research
Tychon Biosciences's top competitors are
Vergent Bioscience,
Luminary Therapeutics, Inc,
Cell Culture Company,
Tract Therapeutics, Inc.,
Predictive Oncology,
Diamedica Therapeutics Inc.,
Oneome,
Dystrogen Therapeutics,
Mekanistic Therapeutics,
Invenshure, Llc.
Tychon Biosciences's categories are Biotechnology Research
Tychon Biosciences's founding year is 2015
